Amgen Ends Crohn's Disease Collaboration, Eliminating Over $500M in Milestone Potential
TCRX sits 16% above its 52-week low of $0.716 on light trading volume (0.3× avg).
Summary
Amgen terminated its Crohn's disease collaboration with TScan, eliminating over $500 million in potential milestone payments and royalties. The termination is effective November 10, 2026, with no penalty to TScan.
Key Events · M&A and Partnerships · TCRX
-
Amgen Terminates Collaboration
Amgen elected to terminate the Research Collaboration and License Agreement dated May 8, 2023, effective November 10, 2026, with no early termination penalty.
-
Loss of Milestone and Royalty Upside
TScan loses access to over $500 million in success-based milestone payments and tiered single-digit royalties on net sales, though the $30 million upfront payment is retained.
-
Wind-Down Obligations
TScan must use commercially reasonable efforts to wind down its activities under the current research plan promptly and efficiently.
-
Survival of Obligations
If Amgen or its affiliates continue to exploit product candidates, applicable milestone and royalty obligations will survive in accordance with the agreement.
Analysis · TCRX · Life Sciences
Amgen is walking away from the 2023 Crohn's disease research collaboration, effective November 10, 2026. TScan loses access to over $500 million in potential milestone payments and future royalties, though it keeps the $30 million upfront payment already received. This removes a major non-dilutive funding source at a time when the company has warned it may not survive as a going concern and needs to raise capital soon.
At the time of this filing, TCRX was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.9M. The 52-week trading range was $0.72 to $2.57. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.